Akebia Therapeutics Inc. share price logo

Akebia Therapeutics Inc.

NASDAQ: AKBA

Small Cap

$1.24

+0.03

(+2.48%)

as on

Akebia Therapeutics Inc. Stock Performance

as on July 3, 2026 at 2:15 pm IST

  • Day's Low

    $1.16
    $1.24
    downward going graph

    6.45%

    Downside

  • 52 Week's Low

    52 Week's High

    $0.82
    $4.08
    downward going graph

    33.65%

    Downside

    228.93%

    Upside

    downward going graph

Akebia Therapeutics Inc. share price movements today

Previous Close
$1.21
Open
$1.22
Volume
4.0M
Day's Low - High
$1.16 - $1.24
52 Week Low - High
$0.82 - $4.08

Akebia Therapeutics Inc. Historical Returns

1 Month Return
+ 27.87 %
3 Month Return
-10.14 %
1 Year Return
-65.75 %
3 Year Return
+ 37.44 %
5 Year Return
-66.58 %

Akebia Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Akebia Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$324.6M

EPS (TTM)

-0.105

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

12.1M

Revenue (TTM)

232.4M

Profit Margin

-8.83%

Return On Equity TTM

-78.96%

Akebia Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Akebia Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Akebia Therapeutics Inc. image
Akebia Therapeutics Inc.
BUY$324.6M-66.58%NA-8.83%NA
United Therapeutics Corporation image
United Therapeutics Corporation
BUY$23.2B201.58%20.2340.62%NA
Viatris Inc. image
Viatris Inc.
HOLD$18.8B13.53%NA-2.04%3.02%
Haleon plc (ADR) image
Haleon plc (ADR)
BUY$41.4BNA19.1815.11%2.0500000000000003%
ZOETIS INC. image
ZOETIS INC.
BUY$30.4B-61.18%11.8828.04%2.82%
See all

Stock Returns calculator for Akebia Therapeutics Inc. Stock including INR - Dollar returns

The Akebia Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Akebia Therapeutics Inc. investment value today

Current value as on today

₹38,170

Returns

-₹61,830

(-61.83%)

Returns from Akebia Therapeutics Inc. Stock

-₹65,746 (-65.75%)

Dollar Impact

₹3,916 (+3.92%)

Analyst Recommendation on Akebia Therapeutics Inc. Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Akebia Therapeutics Inc.. Average target price of $4.2

Akebia Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Akebia Therapeutics Inc..

What analysts predicted

70.48%UPSIDE

Target Price

$4.2

Current Price

$1.24

Analyzed by

9 Analysts

Target

$4.20

Akebia Therapeutics Inc. target price $4.2, a slight upside of 70.48% compared to current price of $1.24. According to 9 analysts rating.

Indian Investors' Interest in Akebia Therapeutics Inc. Stock

Search interest for Akebia Therapeutics Inc. Stock has increased by 211% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:211% versus previous 30 day period

Akebia Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
56
32
43
37
46
57
62
58
57
53
Gross Profit
37
29
35
23
26
49
52
49
45
40
Operating Income
1
-14
-8
-12
-14
13
14
4
-8
-4
EBITDA
11
-4
1
-4
-6
14
7
6
-6
-13
Interest Expense
1
2
2
6
6
7
6
4
4
4
Depreciation
14
9
9
9
9
0
0
0
0
0
Income Before Tax
0
-17
-8
-20
-22
6
0
1
-11
-8
Income Tax Expense
0
9
-
-
-
-
-
0
1
0
Net Income
0
-17
-8
-20
-22
6
0
0
-12
-9
Net Profit Margin
1.09%
-55.16%
-19.66%
-53.54%
-49.04%
10.66%
0.40%
0.92%
-21.25%
-16.91%

Akebia Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
177
207
335
295
213
292
194
160
236
Gross Profit
-114
177
200
189
0
60
269
120
97
196
Operating Income
-136
-79
-178
-286
-376
-265
-80
-46
-50
23
EBITDA
-136
-76
-175
-247
-342
-227
3
-8
-13
21
Interest Expense
0
2
6
38
8
19
15
6
18
24
Depreciation
-
0
2
38
33
37
37
37
37
1
Income Before Tax
-135
-76
-171
-286
-383
-282
-94
-51
-69
-3
Income Tax Expense
0
-2
-28
-6
-33
-37
13
41
-
1
Net Income
-135
-76
-171
-279
-349
-244
-94
-51
-69
-5
Net Profit Margin
-8843.45%
-43.21%
-82.75%
-83.48%
-118.48%
-114.65%
-32.22%
-26.68%
-43.33%
-2.26%

Akebia Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-17
-8
-20
-22
6
0
0
-12
-9
Operating Cash Flow
-19
-10
-6
-4
-13
22
28
31
-21
Investing Cash Flow
-
0
0
0
0
0
0
-7
0
Financing Cash Flow
18
7
1
22
74
1
1
-4
0
Change in Cash
0
-2
-5
17
61
23
29
18
-22

Akebia Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-76
-143
-279
-383
-282
-92
-51
-69
-5
Operating Cash Flow
-56
-97
-257
-110
-252
-73
-23
-40
67
Investing Cash Flow
-177
36
211
-40
39
0
-
0
-7
Financing Cash Flow
116
96
88
231
133
14
-25
49
72
Change in Cash
-117
35
42
81
-79
-58
-48
8
132

Global Institutional Holdings in Akebia Therapeutics Inc.

Funds
Holdings
BlackRock Inc
6.97%
Great Point Partners LLC
0.75%
UBS Group AG
1.36%
Vanguard Group Inc
5.97%
Morgan Stanley - Brokerage Accounts
0.46%
See all

Akebia Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 30 June

    Tue, 06:15 PM

    -

    Akebia and U.S. Renal Care report positive interim results from VOICE trial, leading to early trial halt due to safety outcomes.

Insights on Akebia Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AKBA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, AKBA stock has moved up by 27.9%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -12.24M → -9.05M (in $), with an average increase of 35.2% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, SANDOZ GROUP AG SPONSORED ADS Switzerland has given 103.4% return, outperforming this stock by 169.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 62.47M → 53.54M (in $), with an average decrease of 5.0% per quarter

About Akebia Therapeutics Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
OrganisationAkebia Therapeutics Inc.
Headquarters245 First Street, Cambridge, MA, United States, 02142
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. John P. Butler MBA
E-voting on sharesClick here to vote

Key Management of Akebia Therapeutics Inc.

Name

Title

Mr. John P. Butler MBA

CEO, President & Director

Mr. Nicholas Grund

Senior VP & Chief Commercial Officer

Mr. Richard C. Malabre

Senior VP & Chief Accounting Officer

Mr. Erik John Ostrowski M.B.A.

Chief Business Officer, Senior VP, CFO & Treasurer

Dr. Steven Keith Burke M.D.

Senior VP and Chief Research & Development Officer

Dr. Justin McCue Ph.D.

Senior VP & Chief Technology Officer

Mercedes Carrasco

Senior Director of Investor & Corporate Communications

Ms. Carolyn M. Rucci

Senior VP, Chief Legal Officer & Secretary

Ms. Meredith Bowman

Senior VP & Chief People Officer

FAQs

What is Akebia Therapeutics Inc. share price today?

Akebia Therapeutics Inc. share price today is $1.24 as on at the close of the market. Akebia Therapeutics Inc. share today touched a day high of $1.24 and a low of $1.16.

What is the 52 week high and 52 week low for Akebia Therapeutics Inc. share?

Akebia Therapeutics Inc. share touched a 52 week high of $4.08 on and a 52 week low of $0.82 on . Akebia Therapeutics Inc. stock price today i.e. is closed at $1.24,which is 69.60% down from its 52 week high and 50.72% up from its 52 week low.

What is Akebia Therapeutics Inc.'s market capitalisation today?

Akebia Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Akebia Therapeutics Inc. Stock (AKBA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Akebia Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Akebia Therapeutics Inc. Shares that will get you 1.2097 shares as per Akebia Therapeutics Inc. share price of $1.24 per share as on July 3, 2026 at 8:45 am IST.

What is the minimum amount required to buy Akebia Therapeutics Inc. Stock (AKBA) from India?

Indian investors can start investing in Akebia Therapeutics Inc. (AKBA) shares with as little as ₹95.2 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.00 in Akebia Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Akebia Therapeutics Inc. share’s latest price of $1.24 as on July 3, 2026 at 8:45 am IST, you will get 8.0645 shares of Akebia Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Akebia Therapeutics Inc. has given to Indian investors in the last 5 years?

Akebia Therapeutics Inc. stock has given -66.58% share price returns and 27.38% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?